Mirum Pharmaceuticals, Inc. (MIRM)

NASDAQ: MIRM · IEX Real-Time Price · USD

39.49

+2.12 (5.67%)

At close: Jul 19, 2024, 4:00 PM

40.10

+0.61 (1.54%)

Pre-market: Jul 22, 2024, 7:43 AM EDT

Mirum Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	224	186.37	77.06	19.14	0	0
Revenue Growth (YoY)	133.90%	141.85%	302.66%	-	-	-
Cost of Revenue	59.89	47.04	12.37	1.9	0	0
Gross Profit	164.11	139.34	64.69	17.24	0	0
Selling, General & Admin	161.3	145.88	89.07	59.22	22.69	11.75
Research & Development	111.28	102.61	106.84	131.43	81.61	42.99
Operating Expenses	272.58	248.49	195.91	190.65	104.3	54.74
Operating Income	-108.47	-109.15	-131.22	-173.41	-104.3	-54.74
Interest Expense / Income	14.44	15.11	15.98	17.59	0.34	0
Other Expense / Income	34.24	38.17	-5.13	-107.05	-1.37	-2.21
Pretax Income	-157.15	-162.42	-142.07	-83.95	-103.26	-52.53
Income Tax	1.41	0.99	-6.41	0.04	0.01	0.02
Net Income	-158.56	-163.42	-135.67	-83.99	-103.27	-52.55
Shares Outstanding (Basic)	47	41	34	30	25	11
Shares Outstanding (Diluted)	47	41	34	30	25	11
Shares Change	24.56%	20.31%	12.07%	20.08%	119.84%	-
EPS (Basic)	-3.77	-4.00	-4.01	-2.77	-4.09	-4.58
EPS (Diluted)	-3.77	-4.00	-4.02	-2.77	-4.09	-4.58
Free Cash Flow	-22.04	-71.05	-120.41	-24.78	-89.3	-39.64
Free Cash Flow Per Share	-0.47	-1.74	-3.56	-0.82	-3.54	-3.45
Gross Margin	73.26%	74.76%	83.94%	90.06%	-	-
Operating Margin	-48.43%	-58.57%	-170.28%	-906.12%	-	-
Profit Margin	-70.79%	-87.68%	-176.05%	-438.85%	-	-
Free Cash Flow Margin	-9.84%	-38.12%	-156.26%	-129.49%	-	-
EBITDA	-127.08	-135.87	-122.41	-65.39	-102.31	-52.21
EBITDA Margin	-56.73%	-72.90%	-158.85%	-341.66%	-	-
Depreciation & Amortization	15.63	11.45	3.68	0.98	0.62	0.32
EBIT	-142.71	-147.32	-126.09	-66.36	-102.93	-52.53
EBIT Margin	-63.71%	-79.04%	-163.62%	-346.75%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).